Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.922,16
    +40,66 (+0,12%)
     

  • Dow Jones

    37.986,40
    +211,02 (+0,56%)
     

  • Nasdaq

    15.282,01
    -319,49 (-2,05%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    83,24
    +0,51 (+0,62%)
     

  • Bitcoin EUR

    60.423,04
    +1.040,35 (+1,75%)
     

  • CMC Crypto 200

    1.384,84
    +72,21 (+5,50%)
     

  • Oro

    2.406,70
    +8,70 (+0,36%)
     

  • EUR/USD

    1,0661
    +0,0015 (+0,14%)
     

  • S&P 500

    4.967,23
    -43,89 (-0,88%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.918,09
    -18,48 (-0,37%)
     

  • EUR/GBP

    0,8612
    +0,0056 (+0,65%)
     

  • EUR/CHF

    0,9693
    -0,0017 (-0,18%)
     

  • EUR/CAD

    1,4644
    -0,0007 (-0,05%)
     

iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

iCAD Inc.
·1 minuto per la lettura
iCAD Inc.
iCAD Inc.

NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022.

August 10, 2022 at 4:30 PM ET
Domestic: 888-506-0062                
International: 973-528-0011                
Conference ID: 718241        
Webcast: https://www.webcaster4.com/Webcast/Page/2879/46166

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com

Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com